Belite Bio, Inc (BLTE)

Belite Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	7.27	6.82	3.95	2.38	2.06
Research & Development	29.45	24.84	8.87	7.42	3.69
Operating Expenses	36.72	31.67	12.82	9.8	5.74
Operating Income	-36.72	-31.67	-12.82	-9.8	-5.74
Interest Expense	-0.03	-0.03	-0.02	-	-0.02
Interest & Investment Income	0.07	0.07	0.02	0.01	0.01
Currency Exchange Gain (Loss)	-0	-0	0.17	-	-
Other Non Operating Income (Expenses)	1.39	-	-	0.13	-
Pretax Income	-35.28	-31.62	-12.65	-9.67	-5.75
Income Tax Expense	0.01	0.01	-	-	0
Net Income	-35.29	-31.63	-12.65	-9.67	-5.75
Net Income to Common	-35.29	-31.63	-12.65	-9.67	-5.75
Shares Outstanding (Basic)	29	27	20	10	9
Shares Outstanding (Diluted)	29	27	20	10	9
Shares Change (YoY)	14.96%	33.12%	108.74%	8.87%	-
EPS (Basic)	-1.22	-1.19	-0.63	-1.01	-0.65
EPS (Diluted)	-1.22	-1.19	-0.63	-1.01	-0.65
Free Cash Flow	-	-29.9	-11.85	-7.55	-4.46
Free Cash Flow Per Share	-	-1.12	-0.59	-0.79	-0.51
EBITDA	-36.54	-31.53	-12.76	-9.77	-5.73
D&A For EBITDA	0.18	0.14	0.06	0.03	0.02
EBIT	-36.72	-31.67	-12.82	-9.8	-5.74

Source: S&P Capital IQ. Standard template. Financial Sources.